Neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody-associated disease (MOGAD), and acute disseminated encephalomyelitis (ADEM) are inflammatory demyelinating diseases that are distinct from multiple sclerosis. Each has characteristic pathologic features, serologic markers, and clinical patterns. Misdiagnosing any as MS leads to inappropriate treatment — and the wrong treatment in NMOSD or MOGAD can worsen disease. Modern serology has transformed the field: AQP4-IgG and MOG-IgG testing now distinguish these entities reliably. This page covers the pathology of NMOSD, MOGAD, and ADEM.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Pathology

• Astrocytopathy: NMOSD is a primary astrocyte disease (unlike MS, which is primarily an oligodendrocyte/myelin disease).
• AQP4-IgG-mediated: antibodies against the aquaporin-4 water channel on astrocytic endfeet.
• Complement activation: classical pathway activated at AQP4 sites; complement deposition visible on biopsy.
• Astrocyte loss: extensive in active lesions; GFAP-negative areas surrounded by AQP4-positive reactive astrocytes.
• Secondary demyelination: from astrocyte loss.
• Macrophage infiltration with myelin debris.
• Eosinophils and neutrophils: often prominent (not typical of MS).
• Vasculocentric inflammation: often with vessel wall hyalinization.
• Areas of vacuolation from severe tissue damage.
• Necrosis: more prominent than in MS plaques.

Distribution

Preferential involvement of AQP4-rich regions:

• Optic nerves and chiasm.
• Spinal cord (often longitudinally extensive, ≥ 3 vertebral segments).
• Area postrema (intractable nausea and vomiting — classical NMOSD presentation).
• Hypothalamus / diencephalon.
• Brainstem.
• Periependymal regions.

Clinical Features

• Severe optic neuritis (often bilateral or sequential; severe visual loss).
• Longitudinally extensive transverse myelitis (LETM).
• Area postrema syndrome: intractable nausea, vomiting, hiccups (NMOSD-specific).
• Acute brainstem syndromes.
• Diencephalic syndromes (narcolepsy, SIADH).
• Cerebral syndromes (with characteristic NMOSD MRI patterns).

Diagnosis

• AQP4-IgG serum antibody (live cell-based assay highly specific).
• Wingerchuk 2015 international consensus criteria.
• Distinguish from MS, MOGAD, sarcoidosis.

Treatment

• Acute attack: IV methylprednisolone, plasma exchange.
• Long-term: rituximab, mycophenolate, azathioprine; eculizumab, satralizumab, inebilizumab, ravulizumab approved.
• Avoid certain MS DMTs (interferon, natalizumab, fingolimod) — they can worsen NMOSD.

MOG-Antibody-Associated Disease (MOGAD)

Pathology

• Primarily demyelinating (more like MS than NMOSD in this regard).
• Antibodies against myelin oligodendrocyte glycoprotein (MOG).
• Macrophage-mediated demyelination with relative oligodendrocyte preservation.
• Patchy demyelination, often perivenular.
• Less astrocyte injury than NMOSD.
• Often partial remyelination of lesions over time.
• Less axonal damage than MS or NMOSD acute lesions.

Distribution

• Optic nerves (often bilateral simultaneous).
• Spinal cord (longitudinally extensive).
• Brainstem and cerebellum.
• Often cortical involvement with leptomeningeal enhancement.
• ADEM-like presentations in children.

Clinical Features

• Optic neuritis (often severe, bilateral, recovery often better than NMOSD).
• Transverse myelitis.
• ADEM-like illness in children.
• Cerebral cortical encephalitis with seizures.
• Often monophasic, but relapsing in 50% or more.
• Recovery often better than NMOSD.

Diagnosis

• MOG-IgG serum antibody (live cell-based assay, full-length human MOG).
• 2023 International MOGAD diagnostic criteria.
• Antibody titer relates to disease activity in some patients.

Treatment

• Acute: high-dose steroids, plasma exchange.
• Chronic: prolonged steroid tapers; IVIG, rituximab, MMF, azathioprine for relapsing course.
• Some patients have monophasic illness; chronic immunosuppression individualized.

Acute Disseminated Encephalomyelitis (ADEM)

Pathology

• Perivenous demyelination: discrete small zones of demyelination centered on small veins, with surrounding inflammation. This is the key distinguishing histologic feature from MS (which has confluent plaques).
• Perivascular lymphocytic infiltration.
• Macrophage infiltration.
• Reactive astrogliosis.
• Sparse cortical or subcortical involvement compared to white matter.
• Often relative axonal preservation.

Pathogenesis

Post-infectious or post-vaccinal autoimmune demyelinating disease. Often follows:

• Upper respiratory infection.
• Measles, varicella, mycoplasma, EBV, influenza, COVID-19.
• Vaccination (rare, more historical concern).

Molecular mimicry between microbial and myelin antigens hypothesized.

Clinical Features

• Children > adults.
• Days to weeks after antecedent infection or vaccine.
• Acute multifocal neurologic dysfunction.
• Encephalopathy (often prominent — required by some criteria for ADEM diagnosis).
• Seizures.
• Cranial neuropathies.
• Spinal cord involvement.
• Usually monophasic.

Imaging

• Multiple T2/FLAIR hyperintense lesions in white matter, basal ganglia, thalamus, brainstem, cerebellum.
• Lesions of similar age (single attack, single pathology).
• Often large, ill-defined.
• Variable enhancement.
• Recovery with treatment in most.

Treatment

• High-dose IV methylprednisolone.
• Plasma exchange or IVIG if no response.
• Most patients recover substantially.
• Recurrent or multiphasic ADEM (now considered MOGAD in many cases): additional immunosuppression.

Distinguishing MS, NMOSD, MOGAD, ADEM

🔍 Did You Know?

The discovery of AQP4-IgG by Vanda Lennon and colleagues at Mayo Clinic in 2004 — initially named “NMO-IgG” — transformed neuromyelitis optica from a clinical phenotype into a defined disease entity. Before AQP4-IgG, NMO was thought to be a severe variant of multiple sclerosis. The discovery that 70-80% of NMO patients had antibodies against a specific astrocytic water channel made several things clear at once: NMO is a primary astrocyte disease (not an oligodendrocyte disease like MS), the pathology of NMO lesions reflects complement-mediated astrocyte damage (not the T-cell-mediated myelin attack of MS), and the disease was distinct enough to require different treatment. The years that followed yielded eculizumab, satralizumab, inebilizumab, and ravulizumab — all approved specifically for AQP4-IgG-positive NMOSD with dramatic efficacy. The story repeated with MOG-IgG a decade later: what was thought to be “AQP4-negative NMOSD” or “MS variant” was found to be a separate disease with antibodies against myelin oligodendrocyte glycoprotein. The MOGAD diagnostic criteria followed in 2023. The lesson: autoimmune demyelinating disease classifications have changed dramatically, and any patient with optic neuritis or transverse myelitis now requires AQP4-IgG and MOG-IgG testing before any MS-directed therapy is started. The wrong DMT in NMOSD can worsen attacks; the right targeted therapy can prevent them. The serologic revolution in MS-related disease is one of the most consequential examples in neurology of antibody-defined disease entities replacing clinical phenotypes.

Pitfalls and Pearls

• NMOSD: astrocytopathy from AQP4-IgG; eosinophils/neutrophils; complement; longitudinally extensive spinal cord; area postrema syndrome; bilateral severe optic neuritis.
• MOGAD: demyelinating disease with MOG-IgG; better recovery than NMOSD; cortical encephalitis with seizures; bilateral simultaneous optic neuritis; ADEM-like in children.
• ADEM: perivenous demyelination (distinguishes from MS); post-infectious/post-vaccinal; monophasic in most.
• Recurrent or multiphasic ADEM: often turns out to be MOGAD.
• AQP4-IgG cell-based assay: highly specific.
• MOG-IgG full-length human cell-based assay: standard test.
• Interferon, natalizumab, fingolimod: can worsen NMOSD; avoid.
• Plasma exchange: effective for severe acute attacks of all four diseases.
• Eculizumab, satralizumab, inebilizumab, ravulizumab: AQP4-IgG+ NMOSD specific.
• Rituximab, MMF, azathioprine: MOGAD; also used in NMOSD.
• OCBs in CSF: ~90% MS, often absent in NMOSD/MOGAD/ADEM.
• Longitudinally extensive myelitis (LETM) ≥ 3 segments: NMOSD or MOGAD until proven otherwise.
• Area postrema syndrome (intractable nausea/vomiting/hiccups): highly specific for NMOSD.
• Cortical encephalitis with seizures: emerging MOGAD presentation.

References

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
3. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.
4. Tenembaum S, Chitnis T, Ness J, Hahn JS; International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology. 2007;68(16 Suppl 2):S23-S36.
5. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125(7):1450-1461.
6. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89-102.